| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Drugs, Generic | 34 | 2021 | 448 | 8.540 |
Why?
|
| Product Surveillance, Postmarketing | 21 | 2019 | 452 | 6.050 |
Why?
|
| Pharmacoepidemiology | 22 | 2022 | 350 | 4.570 |
Why?
|
| Warfarin | 22 | 2022 | 1477 | 3.520 |
Why?
|
| Drug Approval | 15 | 2018 | 812 | 3.190 |
Why?
|
| Drug Interactions | 17 | 2021 | 1415 | 2.870 |
Why?
|
| Drug Utilization | 14 | 2021 | 1186 | 2.820 |
Why?
|
| Propensity Score | 35 | 2022 | 1912 | 2.720 |
Why?
|
| Anticoagulants | 26 | 2022 | 4785 | 2.690 |
Why?
|
| Databases, Factual | 57 | 2021 | 7963 | 2.580 |
Why?
|
| Drug Substitution | 10 | 2021 | 290 | 2.570 |
Why?
|
| Adverse Drug Reaction Reporting Systems | 15 | 2020 | 494 | 2.140 |
Why?
|
| Medication Adherence | 21 | 2021 | 2175 | 2.040 |
Why?
|
| Research Design | 18 | 2022 | 6174 | 2.030 |
Why?
|
| Drug Prescriptions | 16 | 2021 | 1669 | 1.930 |
Why?
|
| Prescription Drugs | 10 | 2021 | 631 | 1.890 |
Why?
|
| Cross-Over Studies | 12 | 2021 | 2079 | 1.880 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 18 | 2019 | 3245 | 1.700 |
Why?
|
| Antithrombins | 5 | 2021 | 292 | 1.660 |
Why?
|
| Atrial Fibrillation | 15 | 2021 | 5031 | 1.530 |
Why?
|
| Adrenergic beta-Antagonists | 6 | 2018 | 1241 | 1.510 |
Why?
|
| United States Food and Drug Administration | 22 | 2021 | 1661 | 1.500 |
Why?
|
| Epidemiologic Research Design | 5 | 2019 | 368 | 1.440 |
Why?
|
| Electronic Health Records | 18 | 2021 | 4810 | 1.440 |
Why?
|
| Cohort Studies | 66 | 2023 | 41464 | 1.380 |
Why?
|
| Sentinel Surveillance | 6 | 2018 | 291 | 1.370 |
Why?
|
| Angioedema | 5 | 2019 | 184 | 1.370 |
Why?
|
| Gastrointestinal Hemorrhage | 12 | 2020 | 1116 | 1.350 |
Why?
|
| Ticlopidine | 5 | 2017 | 730 | 1.330 |
Why?
|
| Comparative Effectiveness Research | 7 | 2018 | 708 | 1.280 |
Why?
|
| Rare Diseases | 4 | 2015 | 622 | 1.270 |
Why?
|
| Analgesics, Opioid | 13 | 2022 | 3805 | 1.260 |
Why?
|
| Platelet Aggregation Inhibitors | 6 | 2018 | 2746 | 1.200 |
Why?
|
| Rhabdomyolysis | 4 | 2019 | 152 | 1.190 |
Why?
|
| Calcium Channel Blockers | 4 | 2020 | 694 | 1.170 |
Why?
|
| Pyridones | 6 | 2022 | 808 | 1.130 |
Why?
|
| United States | 100 | 2021 | 72292 | 1.130 |
Why?
|
| Computer Simulation | 15 | 2020 | 6233 | 1.120 |
Why?
|
| Patient Preference | 7 | 2020 | 925 | 1.120 |
Why?
|
| Drug Monitoring | 5 | 2018 | 960 | 1.090 |
Why?
|
| Hypolipidemic Agents | 7 | 2018 | 609 | 1.060 |
Why?
|
| Medicare | 20 | 2021 | 6774 | 1.050 |
Why?
|
| Angiotensin-Converting Enzyme Inhibitors | 6 | 2018 | 1517 | 1.030 |
Why?
|
| Hemorrhage | 13 | 2020 | 3418 | 1.020 |
Why?
|
| Epidemiologic Methods | 6 | 2017 | 1335 | 1.010 |
Why?
|
| Angiotensin Receptor Antagonists | 4 | 2020 | 1040 | 0.960 |
Why?
|
| Insurance, Health | 8 | 2020 | 2495 | 0.950 |
Why?
|
| Humans | 252 | 2023 | 760740 | 0.930 |
Why?
|
| Insurance Claim Review | 8 | 2021 | 741 | 0.910 |
Why?
|
| Biological Products | 4 | 2022 | 912 | 0.910 |
Why?
|
| Baclofen | 2 | 2022 | 120 | 0.910 |
Why?
|
| Therapeutic Equivalency | 9 | 2018 | 134 | 0.900 |
Why?
|
| Anticonvulsants | 6 | 2016 | 1910 | 0.880 |
Why?
|
| Venous Thromboembolism | 6 | 2022 | 1866 | 0.870 |
Why?
|
| Purinergic P2Y Receptor Antagonists | 2 | 2017 | 284 | 0.860 |
Why?
|
| Hypoglycemic Agents | 14 | 2020 | 3085 | 0.860 |
Why?
|
| Comorbidity | 13 | 2022 | 10507 | 0.850 |
Why?
|
| Carisoprodol | 1 | 2022 | 5 | 0.830 |
Why?
|
| Methocarbamol | 1 | 2022 | 8 | 0.830 |
Why?
|
| Drug Evaluation | 2 | 2021 | 641 | 0.830 |
Why?
|
| Aged | 98 | 2023 | 169092 | 0.820 |
Why?
|
| Pyrazoles | 6 | 2022 | 2008 | 0.800 |
Why?
|
| Tetrazoles | 2 | 2018 | 909 | 0.800 |
Why?
|
| Psoriasis | 2 | 2022 | 944 | 0.800 |
Why?
|
| Drug Recalls | 2 | 2020 | 20 | 0.790 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 9 | 2022 | 2270 | 0.790 |
Why?
|
| Ondansetron | 1 | 2022 | 95 | 0.780 |
Why?
|
| Data Mining | 6 | 2021 | 551 | 0.780 |
Why?
|
| Hospitalization | 16 | 2022 | 10708 | 0.780 |
Why?
|
| Insurance, Pharmaceutical Services | 4 | 2020 | 348 | 0.750 |
Why?
|
| Coronary Artery Bypass | 5 | 2017 | 2188 | 0.750 |
Why?
|
| Female | 140 | 2023 | 392203 | 0.730 |
Why?
|
| Male | 133 | 2023 | 360402 | 0.730 |
Why?
|
| Prescriptions | 2 | 2022 | 386 | 0.710 |
Why?
|
| Data Interpretation, Statistical | 12 | 2021 | 2689 | 0.710 |
Why?
|
| Neuromuscular Agents | 1 | 2022 | 148 | 0.710 |
Why?
|
| Lorazepam | 1 | 2021 | 155 | 0.710 |
Why?
|
| Quality-Adjusted Life Years | 3 | 2015 | 1723 | 0.700 |
Why?
|
| Pharmacies | 3 | 2021 | 167 | 0.690 |
Why?
|
| Antihypertensive Agents | 7 | 2019 | 2018 | 0.680 |
Why?
|
| Arthritis, Psoriatic | 1 | 2022 | 219 | 0.660 |
Why?
|
| Hyperlipidemias | 5 | 2018 | 770 | 0.660 |
Why?
|
| Withholding Treatment | 2 | 2021 | 615 | 0.650 |
Why?
|
| Case-Control Studies | 13 | 2021 | 22153 | 0.640 |
Why?
|
| Middle Aged | 98 | 2022 | 220603 | 0.640 |
Why?
|
| Drug Costs | 9 | 2021 | 1183 | 0.630 |
Why?
|
| Blood Loss, Surgical | 2 | 2015 | 636 | 0.620 |
Why?
|
| Risk Assessment | 25 | 2021 | 23974 | 0.620 |
Why?
|
| Marketing | 2 | 2018 | 220 | 0.620 |
Why?
|
| Wet Macular Degeneration | 1 | 2020 | 162 | 0.600 |
Why?
|
| Epilepsy | 5 | 2016 | 3303 | 0.600 |
Why?
|
| Algorithms | 11 | 2022 | 14024 | 0.590 |
Why?
|
| Drug Therapy, Combination | 7 | 2023 | 6305 | 0.590 |
Why?
|
| Delivery, Obstetric | 3 | 2019 | 939 | 0.580 |
Why?
|
| Renal Insufficiency | 2 | 2016 | 808 | 0.570 |
Why?
|
| Trust | 3 | 2017 | 529 | 0.560 |
Why?
|
| Azithromycin | 3 | 2022 | 199 | 0.550 |
Why?
|
| Choroidal Neovascularization | 1 | 2020 | 363 | 0.550 |
Why?
|
| Pulmonary Disease, Chronic Obstructive | 3 | 2023 | 3204 | 0.550 |
Why?
|
| Niacin | 1 | 2017 | 118 | 0.550 |
Why?
|
| Thromboembolism | 3 | 2020 | 991 | 0.540 |
Why?
|
| International Classification of Diseases | 3 | 2018 | 912 | 0.540 |
Why?
|
| Ketolides | 2 | 2014 | 12 | 0.530 |
Why?
|
| Drug Utilization Review | 1 | 2017 | 248 | 0.530 |
Why?
|
| Methylprednisolone | 1 | 2017 | 385 | 0.530 |
Why?
|
| Acute Coronary Syndrome | 3 | 2018 | 2190 | 0.530 |
Why?
|
| Inappropriate Prescribing | 1 | 2019 | 212 | 0.520 |
Why?
|
| Pharmaceutical Preparations | 5 | 2021 | 1086 | 0.520 |
Why?
|
| Public Opinion | 2 | 2019 | 484 | 0.520 |
Why?
|
| Thiazolidinediones | 2 | 2016 | 460 | 0.510 |
Why?
|
| Intracranial Hemorrhages | 3 | 2018 | 809 | 0.510 |
Why?
|
| Choice Behavior | 2 | 2019 | 825 | 0.500 |
Why?
|
| Peer Review | 1 | 2017 | 217 | 0.500 |
Why?
|
| Parkinson Disease, Secondary | 1 | 2015 | 122 | 0.490 |
Why?
|
| Drug Evaluation, Preclinical | 1 | 2020 | 1333 | 0.490 |
Why?
|
| Models, Theoretical | 3 | 2016 | 3567 | 0.490 |
Why?
|
| Stroke | 11 | 2021 | 9715 | 0.480 |
Why?
|
| Private Sector | 1 | 2018 | 394 | 0.480 |
Why?
|
| Diabetes Mellitus | 10 | 2018 | 5838 | 0.470 |
Why?
|
| Aged, 80 and over | 30 | 2022 | 58919 | 0.470 |
Why?
|
| Myocardial Infarction | 11 | 2020 | 11458 | 0.470 |
Why?
|
| Statistics as Topic | 3 | 2018 | 2358 | 0.460 |
Why?
|
| Community Pharmacy Services | 2 | 2018 | 52 | 0.460 |
Why?
|
| Sulfonylurea Compounds | 4 | 2020 | 219 | 0.460 |
Why?
|
| Receptors, Dopamine D3 | 1 | 2014 | 108 | 0.460 |
Why?
|
| Privacy | 1 | 2016 | 233 | 0.450 |
Why?
|
| Compulsive Behavior | 1 | 2014 | 117 | 0.450 |
Why?
|
| Pneumonia | 3 | 2023 | 2143 | 0.450 |
Why?
|
| Health Services | 2 | 2022 | 751 | 0.440 |
Why?
|
| Obstetric Labor Complications | 2 | 2019 | 236 | 0.440 |
Why?
|
| Information Systems | 1 | 2015 | 396 | 0.440 |
Why?
|
| Logistic Models | 14 | 2020 | 13248 | 0.430 |
Why?
|
| Bone Density Conservation Agents | 3 | 2016 | 794 | 0.430 |
Why?
|
| Time Factors | 28 | 2022 | 39908 | 0.430 |
Why?
|
| Incidence | 20 | 2020 | 21339 | 0.430 |
Why?
|
| Cardiovascular Diseases | 12 | 2022 | 15498 | 0.420 |
Why?
|
| Models, Statistical | 7 | 2019 | 5074 | 0.420 |
Why?
|
| Disease | 2 | 2017 | 670 | 0.420 |
Why?
|
| Legislation, Drug | 3 | 2021 | 214 | 0.410 |
Why?
|
| Patient Advocacy | 1 | 2015 | 360 | 0.410 |
Why?
|
| Glaucoma, Open-Angle | 1 | 2019 | 738 | 0.410 |
Why?
|
| Pregnancy Complications | 4 | 2019 | 2948 | 0.410 |
Why?
|
| Odds Ratio | 10 | 2020 | 9644 | 0.410 |
Why?
|
| Thiophenes | 2 | 2014 | 569 | 0.410 |
Why?
|
| Research | 3 | 2017 | 1977 | 0.400 |
Why?
|
| Evidence-Based Medicine | 6 | 2020 | 3680 | 0.400 |
Why?
|
| Dopamine Agonists | 1 | 2014 | 352 | 0.400 |
Why?
|
| Proportional Hazards Models | 15 | 2020 | 12448 | 0.400 |
Why?
|
| Drug Therapy | 1 | 2015 | 503 | 0.390 |
Why?
|
| Tamoxifen | 1 | 2016 | 965 | 0.390 |
Why?
|
| Imidazoles | 1 | 2018 | 1175 | 0.390 |
Why?
|
| Severity of Illness Index | 7 | 2020 | 15829 | 0.390 |
Why?
|
| Health Knowledge, Attitudes, Practice | 8 | 2020 | 4010 | 0.390 |
Why?
|
| Automation | 1 | 2014 | 585 | 0.380 |
Why?
|
| Models, Biological | 2 | 2018 | 9461 | 0.380 |
Why?
|
| Thiazoles | 2 | 2021 | 1517 | 0.380 |
Why?
|
| Parkinson Disease | 3 | 2016 | 2878 | 0.380 |
Why?
|
| Antidepressive Agents | 3 | 2019 | 2896 | 0.370 |
Why?
|
| Gambling | 1 | 2014 | 258 | 0.370 |
Why?
|
| Dexamethasone | 2 | 2017 | 1946 | 0.370 |
Why?
|
| Immunosuppressive Agents | 3 | 2019 | 4172 | 0.370 |
Why?
|
| Simvastatin | 3 | 2020 | 346 | 0.360 |
Why?
|
| Safety | 1 | 2015 | 1149 | 0.360 |
Why?
|
| Oxycodone | 2 | 2022 | 139 | 0.360 |
Why?
|
| Adult | 60 | 2022 | 220995 | 0.360 |
Why?
|
| Italy | 5 | 2017 | 842 | 0.350 |
Why?
|
| Smoking | 4 | 2020 | 9054 | 0.350 |
Why?
|
| Treatment Outcome | 25 | 2021 | 64572 | 0.350 |
Why?
|
| Sepsis | 2 | 2022 | 2585 | 0.340 |
Why?
|
| Clinical Coding | 3 | 2021 | 181 | 0.340 |
Why?
|
| Clarithromycin | 2 | 2020 | 86 | 0.340 |
Why?
|
| Hydrocortisone | 1 | 2017 | 1819 | 0.340 |
Why?
|
| Retrospective Studies | 35 | 2022 | 80583 | 0.330 |
Why?
|
| Forecasting | 1 | 2018 | 2924 | 0.330 |
Why?
|
| International Normalized Ratio | 4 | 2021 | 381 | 0.330 |
Why?
|
| Commerce | 1 | 2014 | 608 | 0.330 |
Why?
|
| Cyclooxygenase 2 Inhibitors | 3 | 2016 | 321 | 0.330 |
Why?
|
| Administration, Oral | 8 | 2022 | 4010 | 0.320 |
Why?
|
| Gastrointestinal Diseases | 1 | 2018 | 1202 | 0.320 |
Why?
|
| Aprotinin | 1 | 2009 | 94 | 0.320 |
Why?
|
| Pyridines | 3 | 2021 | 2875 | 0.320 |
Why?
|
| Reimbursement Mechanisms | 1 | 2014 | 667 | 0.320 |
Why?
|
| Monte Carlo Method | 4 | 2019 | 1257 | 0.320 |
Why?
|
| Cytochrome P-450 CYP3A | 2 | 2019 | 114 | 0.310 |
Why?
|
| Metoprolol | 2 | 2018 | 90 | 0.310 |
Why?
|
| Glipizide | 5 | 2020 | 48 | 0.300 |
Why?
|
| Randomized Controlled Trials as Topic | 10 | 2018 | 10203 | 0.300 |
Why?
|
| Antineoplastic Agents, Hormonal | 1 | 2016 | 1520 | 0.300 |
Why?
|
| Pharmacists | 3 | 2020 | 259 | 0.300 |
Why?
|
| Disease Progression | 3 | 2020 | 13495 | 0.300 |
Why?
|
| Length of Stay | 3 | 2017 | 6418 | 0.290 |
Why?
|
| Taiwan | 3 | 2019 | 521 | 0.290 |
Why?
|
| Pennsylvania | 4 | 2013 | 612 | 0.290 |
Why?
|
| Pharmaceutical Services | 3 | 2018 | 141 | 0.290 |
Why?
|
| Hypoglycemia | 5 | 2019 | 883 | 0.290 |
Why?
|
| Delivery of Health Care | 4 | 2020 | 5334 | 0.290 |
Why?
|
| New Jersey | 3 | 2013 | 295 | 0.280 |
Why?
|
| Fungemia | 1 | 2007 | 57 | 0.280 |
Why?
|
| Cholesterol | 1 | 2016 | 2902 | 0.280 |
Why?
|
| Benzodiazepines | 3 | 2022 | 1133 | 0.280 |
Why?
|
| Death, Sudden, Cardiac | 3 | 2020 | 1551 | 0.280 |
Why?
|
| Patient Readmission | 2 | 2018 | 3269 | 0.270 |
Why?
|
| Follow-Up Studies | 14 | 2020 | 39062 | 0.270 |
Why?
|
| Renal Insufficiency, Chronic | 2 | 2018 | 2252 | 0.270 |
Why?
|
| Piperazines | 2 | 2014 | 2521 | 0.270 |
Why?
|
| Treatment Failure | 1 | 2012 | 2635 | 0.270 |
Why?
|
| Narcotic Antagonists | 2 | 2022 | 585 | 0.270 |
Why?
|
| Bronchodilator Agents | 2 | 2023 | 512 | 0.270 |
Why?
|
| Hemostatics | 1 | 2009 | 240 | 0.270 |
Why?
|
| Medicare Part D | 2 | 2021 | 354 | 0.260 |
Why?
|
| Risk Factors | 30 | 2021 | 74128 | 0.260 |
Why?
|
| Aortic Coarctation | 2 | 2018 | 275 | 0.260 |
Why?
|
| Decision Support Techniques | 2 | 2019 | 1999 | 0.260 |
Why?
|
| Substance-Related Disorders | 1 | 2022 | 4416 | 0.250 |
Why?
|
| Lisinopril | 3 | 2016 | 61 | 0.250 |
Why?
|
| Program Development | 1 | 2012 | 1293 | 0.250 |
Why?
|
| Nebulizers and Vaporizers | 2 | 2023 | 139 | 0.250 |
Why?
|
| Glyburide | 4 | 2020 | 116 | 0.250 |
Why?
|
| Cerebral Hemorrhage | 1 | 2016 | 2642 | 0.250 |
Why?
|
| Metformin | 3 | 2019 | 906 | 0.240 |
Why?
|
| Endpoint Determination | 2 | 2019 | 590 | 0.240 |
Why?
|
| Hospital Mortality | 3 | 2018 | 5292 | 0.240 |
Why?
|
| Diabetes Mellitus, Type 2 | 8 | 2020 | 12143 | 0.240 |
Why?
|
| Self Efficacy | 1 | 2009 | 636 | 0.240 |
Why?
|
| Sexual Behavior | 1 | 2014 | 2187 | 0.240 |
Why?
|
| Candidiasis | 1 | 2007 | 365 | 0.240 |
Why?
|
| Clinical Trials as Topic | 4 | 2015 | 7995 | 0.240 |
Why?
|
| Muscarinic Antagonists | 2 | 2023 | 135 | 0.240 |
Why?
|
| Adrenergic beta-2 Receptor Agonists | 2 | 2023 | 111 | 0.240 |
Why?
|
| Brain Ischemia | 1 | 2018 | 3030 | 0.230 |
Why?
|
| Thalidomide | 2 | 2022 | 885 | 0.230 |
Why?
|
| Seizures | 3 | 2016 | 2964 | 0.230 |
Why?
|
| Mortality | 2 | 2017 | 2899 | 0.230 |
Why?
|
| Anti-Bacterial Agents | 7 | 2022 | 7403 | 0.230 |
Why?
|
| Cardiopulmonary Bypass | 1 | 2009 | 1092 | 0.220 |
Why?
|
| Glycopyrrolate | 1 | 2023 | 32 | 0.220 |
Why?
|
| Fractures, Bone | 2 | 2017 | 2045 | 0.220 |
Why?
|
| Young Adult | 19 | 2020 | 59191 | 0.220 |
Why?
|
| Information Storage and Retrieval | 2 | 2019 | 819 | 0.220 |
Why?
|
| Embolism | 2 | 2020 | 399 | 0.210 |
Why?
|
| Medical Records | 2 | 2019 | 1408 | 0.210 |
Why?
|
| Migraine Disorders | 4 | 2009 | 1701 | 0.210 |
Why?
|
| Adrenal Cortex Hormones | 2 | 2023 | 1878 | 0.210 |
Why?
|
| Orphenadrine | 1 | 2022 | 4 | 0.210 |
Why?
|
| Chlorzoxazone | 1 | 2022 | 7 | 0.210 |
Why?
|
| Hypertension | 7 | 2018 | 8532 | 0.210 |
Why?
|
| Caregivers | 1 | 2015 | 2241 | 0.210 |
Why?
|
| Hydrocodone | 1 | 2022 | 48 | 0.200 |
Why?
|
| Antifungal Agents | 1 | 2007 | 753 | 0.200 |
Why?
|
| Fluoroquinolones | 2 | 2022 | 306 | 0.200 |
Why?
|
| Administration, Inhalation | 2 | 2023 | 1156 | 0.200 |
Why?
|
| Amitriptyline | 1 | 2022 | 112 | 0.200 |
Why?
|
| Ciprofloxacin | 3 | 2022 | 312 | 0.200 |
Why?
|
| Adolescent | 19 | 2022 | 88247 | 0.200 |
Why?
|
| Monitoring, Physiologic | 1 | 2009 | 1780 | 0.200 |
Why?
|
| Cardiovascular Agents | 2 | 2018 | 840 | 0.200 |
Why?
|
| Comoros | 1 | 2020 | 12 | 0.190 |
Why?
|
| Rheumatic Diseases | 2 | 2018 | 649 | 0.190 |
Why?
|
| Deductibles and Coinsurance | 2 | 2021 | 316 | 0.190 |
Why?
|
| Denmark | 6 | 2020 | 770 | 0.180 |
Why?
|
| Optometry | 1 | 2020 | 29 | 0.180 |
Why?
|
| Muscle Relaxants, Central | 1 | 2021 | 93 | 0.180 |
Why?
|
| Drug Combinations | 2 | 2018 | 2048 | 0.180 |
Why?
|
| Patient Compliance | 1 | 2011 | 2688 | 0.180 |
Why?
|
| Anti-Inflammatory Agents | 1 | 2010 | 1810 | 0.180 |
Why?
|
| Fenofibrate | 2 | 2017 | 87 | 0.170 |
Why?
|
| Age Factors | 10 | 2020 | 18381 | 0.170 |
Why?
|
| Cerebrovascular Disorders | 2 | 2018 | 1474 | 0.170 |
Why?
|
| Data Collection | 3 | 2019 | 3316 | 0.170 |
Why?
|
| Drug Administration Schedule | 3 | 2018 | 4845 | 0.170 |
Why?
|
| Tablets | 1 | 2020 | 148 | 0.170 |
Why?
|
| Contracts | 1 | 2020 | 60 | 0.170 |
Why?
|
| Veterans | 1 | 2014 | 2649 | 0.170 |
Why?
|
| Outpatients | 3 | 2017 | 1596 | 0.170 |
Why?
|
| Databases as Topic | 2 | 2014 | 473 | 0.170 |
Why?
|
| Risk | 7 | 2020 | 9603 | 0.170 |
Why?
|
| Pharmacy | 1 | 2021 | 91 | 0.170 |
Why?
|
| Health Services Research | 3 | 2018 | 1808 | 0.170 |
Why?
|
| National Health Programs | 2 | 2020 | 440 | 0.170 |
Why?
|
| Vitamin K | 3 | 2020 | 313 | 0.170 |
Why?
|
| Attitude of Health Personnel | 4 | 2020 | 3882 | 0.170 |
Why?
|
| Delayed-Action Preparations | 3 | 2018 | 962 | 0.170 |
Why?
|
| Control Groups | 1 | 2019 | 104 | 0.170 |
Why?
|
| Cost-Benefit Analysis | 4 | 2021 | 5493 | 0.170 |
Why?
|
| Heart Failure | 3 | 2019 | 11670 | 0.170 |
Why?
|
| Confidence Intervals | 3 | 2013 | 2925 | 0.170 |
Why?
|
| Chronic Disease | 4 | 2019 | 9310 | 0.160 |
Why?
|
| Codeine | 2 | 2016 | 51 | 0.160 |
Why?
|
| Arrhythmias, Cardiac | 2 | 2020 | 2234 | 0.160 |
Why?
|
| Urinary Tract Infections | 2 | 2022 | 802 | 0.160 |
Why?
|
| Kaplan-Meier Estimate | 3 | 2019 | 6473 | 0.160 |
Why?
|
| Excitatory Amino Acid Antagonists | 1 | 2021 | 446 | 0.160 |
Why?
|
| Lawyers | 1 | 2019 | 38 | 0.160 |
Why?
|
| Adrenergic beta-1 Receptor Antagonists | 1 | 2018 | 30 | 0.160 |
Why?
|
| Adrenergic Antagonists | 1 | 2018 | 26 | 0.160 |
Why?
|
| Sensitivity and Specificity | 5 | 2020 | 14649 | 0.160 |
Why?
|
| Neoplasms | 10 | 2020 | 22131 | 0.160 |
Why?
|
| Acitretin | 1 | 2018 | 16 | 0.160 |
Why?
|
| Physicians | 1 | 2016 | 4583 | 0.150 |
Why?
|
| Antirheumatic Agents | 2 | 2018 | 1365 | 0.150 |
Why?
|
| Drug Repositioning | 1 | 2020 | 233 | 0.150 |
Why?
|
| Disease Management | 2 | 2018 | 2506 | 0.150 |
Why?
|
| Secondary Prevention | 2 | 2018 | 1470 | 0.150 |
Why?
|
| Diagnostic Techniques and Procedures | 1 | 2020 | 219 | 0.150 |
Why?
|
| Incretins | 1 | 2018 | 99 | 0.150 |
Why?
|
| Decision Making | 3 | 2018 | 3919 | 0.150 |
Why?
|
| Population Surveillance | 2 | 2018 | 2597 | 0.150 |
Why?
|
| Hematinics | 1 | 2020 | 282 | 0.150 |
Why?
|
| Perception | 3 | 2019 | 1199 | 0.150 |
Why?
|
| Sertraline | 1 | 2019 | 209 | 0.150 |
Why?
|
| Clindamycin | 1 | 2018 | 139 | 0.150 |
Why?
|
| Vulnerable Populations | 2 | 2014 | 705 | 0.150 |
Why?
|
| Naloxone | 1 | 2020 | 370 | 0.150 |
Why?
|
| Ventricular Fibrillation | 1 | 2020 | 534 | 0.140 |
Why?
|
| Oxygen Inhalation Therapy | 1 | 2020 | 410 | 0.140 |
Why?
|
| Social Class | 3 | 2019 | 1993 | 0.140 |
Why?
|
| Paroxetine | 2 | 2022 | 182 | 0.140 |
Why?
|
| Focus Groups | 4 | 2016 | 1409 | 0.140 |
Why?
|
| Sex Factors | 6 | 2020 | 10549 | 0.140 |
Why?
|
| Ventricular Dysfunction | 1 | 2018 | 144 | 0.140 |
Why?
|
| Technology | 1 | 2019 | 293 | 0.140 |
Why?
|
| Reproducibility of Results | 8 | 2022 | 20077 | 0.140 |
Why?
|
| Drug Labeling | 2 | 2016 | 248 | 0.140 |
Why?
|
| Medication Therapy Management | 1 | 2018 | 130 | 0.140 |
Why?
|
| Stomach Ulcer | 1 | 2017 | 122 | 0.140 |
Why?
|
| Organic Cation Transporter 1 | 1 | 2016 | 8 | 0.140 |
Why?
|
| Mental Disorders | 1 | 2016 | 6826 | 0.140 |
Why?
|
| Biometry | 1 | 2019 | 561 | 0.130 |
Why?
|
| Erythropoietin | 1 | 2020 | 719 | 0.130 |
Why?
|
| Citalopram | 1 | 2019 | 402 | 0.130 |
Why?
|
| Frail Elderly | 1 | 2021 | 765 | 0.130 |
Why?
|
| Aortic Aneurysm | 1 | 2020 | 648 | 0.130 |
Why?
|
| Guidelines as Topic | 2 | 2019 | 1386 | 0.130 |
Why?
|
| Patient Acceptance of Health Care | 3 | 2018 | 3196 | 0.130 |
Why?
|
| Investments | 1 | 2017 | 147 | 0.130 |
Why?
|
| Depression | 2 | 2022 | 8132 | 0.130 |
Why?
|
| Quality of Health Care | 2 | 2008 | 4325 | 0.130 |
Why?
|
| Likelihood Functions | 1 | 2018 | 991 | 0.120 |
Why?
|
| Dipeptidyl-Peptidase IV Inhibitors | 1 | 2019 | 311 | 0.120 |
Why?
|
| Cyclooxygenase Inhibitors | 1 | 2017 | 361 | 0.120 |
Why?
|
| Medicaid | 4 | 2020 | 2814 | 0.120 |
Why?
|
| Drug Discovery | 2 | 2015 | 1051 | 0.120 |
Why?
|
| Respiratory System Agents | 1 | 2014 | 30 | 0.120 |
Why?
|
| Eye Diseases | 1 | 2020 | 653 | 0.120 |
Why?
|
| Alendronate | 1 | 2016 | 175 | 0.120 |
Why?
|
| Hemoglobins | 2 | 2020 | 1524 | 0.120 |
Why?
|
| Cannabinoids | 1 | 2017 | 172 | 0.120 |
Why?
|
| Mental Health | 1 | 2009 | 3253 | 0.120 |
Why?
|
| Health Care Surveys | 2 | 2019 | 2422 | 0.120 |
Why?
|
| Natural History | 1 | 2013 | 3 | 0.120 |
Why?
|
| Practice Guidelines as Topic | 4 | 2017 | 7390 | 0.110 |
Why?
|
| Bronchitis | 1 | 2014 | 196 | 0.110 |
Why?
|
| Clinical Laboratory Techniques | 2 | 2016 | 745 | 0.110 |
Why?
|
| Medical Record Linkage | 1 | 2015 | 286 | 0.110 |
Why?
|
| France | 3 | 2020 | 492 | 0.110 |
Why?
|
| Ophthalmology | 1 | 2020 | 550 | 0.110 |
Why?
|
| Natural Language Processing | 2 | 2019 | 1166 | 0.110 |
Why?
|
| Cardiac Surgical Procedures | 1 | 2009 | 3621 | 0.110 |
Why?
|
| Health Expenditures | 4 | 2021 | 2363 | 0.110 |
Why?
|
| Kidney | 1 | 2009 | 7044 | 0.110 |
Why?
|
| Biphenyl Compounds | 1 | 2018 | 1007 | 0.110 |
Why?
|
| Postoperative Period | 1 | 2018 | 1812 | 0.110 |
Why?
|
| Databases, Bibliographic | 1 | 2013 | 130 | 0.110 |
Why?
|
| Hypnotics and Sedatives | 1 | 2021 | 1178 | 0.110 |
Why?
|
| Prescription Fees | 1 | 2014 | 153 | 0.110 |
Why?
|
| Confidentiality | 2 | 2014 | 608 | 0.110 |
Why?
|
| Orphan Drug Production | 1 | 2013 | 48 | 0.110 |
Why?
|
| Registries | 4 | 2019 | 8209 | 0.110 |
Why?
|
| Lactones | 1 | 2015 | 316 | 0.110 |
Why?
|
| Enoxaparin | 1 | 2015 | 391 | 0.110 |
Why?
|
| Meta-Analysis as Topic | 1 | 2018 | 1380 | 0.110 |
Why?
|
| Disseminated Intravascular Coagulation | 1 | 2013 | 186 | 0.110 |
Why?
|
| Sulfones | 1 | 2015 | 447 | 0.100 |
Why?
|
| Anti-Ulcer Agents | 1 | 2013 | 112 | 0.100 |
Why?
|
| Myocardial Revascularization | 1 | 2016 | 790 | 0.100 |
Why?
|
| Isoxazoles | 1 | 2014 | 232 | 0.100 |
Why?
|
| Adenosine | 1 | 2017 | 805 | 0.100 |
Why?
|
| Stockings, Compression | 1 | 2012 | 36 | 0.100 |
Why?
|
| Emergency Service, Hospital | 4 | 2022 | 7873 | 0.100 |
Why?
|
| Antipsychotic Agents | 3 | 2016 | 3067 | 0.100 |
Why?
|
| Prenatal Diagnosis | 1 | 2019 | 1265 | 0.100 |
Why?
|
| Leisure Activities | 1 | 2014 | 308 | 0.100 |
Why?
|
| Quality of Life | 3 | 2015 | 13359 | 0.100 |
Why?
|
| Histamine H2 Antagonists | 1 | 2013 | 165 | 0.100 |
Why?
|
| Drug Industry | 1 | 2018 | 788 | 0.100 |
Why?
|
| Rheumatology | 1 | 2018 | 615 | 0.100 |
Why?
|
| Socioeconomic Factors | 5 | 2020 | 7805 | 0.100 |
Why?
|
| Health Planning Guidelines | 1 | 2012 | 151 | 0.100 |
Why?
|
| Sulfonamides | 2 | 2014 | 1977 | 0.100 |
Why?
|
| Cephalosporins | 1 | 2013 | 198 | 0.100 |
Why?
|
| Prospective Studies | 8 | 2019 | 54364 | 0.100 |
Why?
|
| National Cancer Institute (U.S.) | 1 | 2013 | 296 | 0.100 |
Why?
|
| beta-Alanine | 1 | 2012 | 82 | 0.100 |
Why?
|
| Primary Health Care | 2 | 2019 | 4677 | 0.100 |
Why?
|
| Glomerular Filtration Rate | 2 | 2018 | 2174 | 0.100 |
Why?
|
| Medical Informatics Applications | 1 | 2013 | 179 | 0.100 |
Why?
|
| Methotrexate | 1 | 2018 | 1716 | 0.100 |
Why?
|
| Suicide | 1 | 2022 | 1601 | 0.090 |
Why?
|
| Consumer Health Information | 1 | 2014 | 215 | 0.090 |
Why?
|
| Osteoporotic Fractures | 1 | 2016 | 410 | 0.090 |
Why?
|
| Life Change Events | 1 | 2016 | 953 | 0.090 |
Why?
|
| Anemia | 1 | 2020 | 1504 | 0.090 |
Why?
|
| Clostridium Infections | 1 | 2018 | 557 | 0.090 |
Why?
|
| Cholesterol, HDL | 1 | 2017 | 1810 | 0.090 |
Why?
|
| Enterocolitis, Pseudomembranous | 1 | 2013 | 264 | 0.090 |
Why?
|
| Diarrhea | 1 | 2018 | 1317 | 0.090 |
Why?
|
| Quinolones | 1 | 2014 | 378 | 0.090 |
Why?
|
| False Negative Reactions | 1 | 2012 | 573 | 0.090 |
Why?
|
| Dose-Response Relationship, Drug | 4 | 2017 | 10754 | 0.090 |
Why?
|
| Heparin, Low-Molecular-Weight | 1 | 2012 | 344 | 0.090 |
Why?
|
| Primary Prevention | 1 | 2018 | 1185 | 0.090 |
Why?
|
| Interview, Psychological | 1 | 2013 | 809 | 0.090 |
Why?
|
| Regression Analysis | 2 | 2016 | 6339 | 0.090 |
Why?
|
| British Columbia | 1 | 2010 | 241 | 0.090 |
Why?
|
| Pregnancy | 5 | 2019 | 29869 | 0.090 |
Why?
|
| Vancomycin | 1 | 2013 | 503 | 0.080 |
Why?
|
| Sodium Chloride Symporter Inhibitors | 1 | 2010 | 78 | 0.080 |
Why?
|
| Celiac Disease | 1 | 2018 | 819 | 0.080 |
Why?
|
| Adrenergic alpha-Antagonists | 1 | 2010 | 174 | 0.080 |
Why?
|
| Recurrence | 2 | 2022 | 8426 | 0.080 |
Why?
|
| Respiration, Artificial | 1 | 2020 | 2630 | 0.080 |
Why?
|
| Prognosis | 5 | 2022 | 29601 | 0.080 |
Why?
|
| Extracorporeal Membrane Oxygenation | 1 | 2020 | 1462 | 0.080 |
Why?
|
| False Positive Reactions | 1 | 2012 | 957 | 0.080 |
Why?
|
| Equipment and Supplies | 1 | 2012 | 273 | 0.080 |
Why?
|
| Benchmarking | 1 | 2015 | 1045 | 0.080 |
Why?
|
| Morpholines | 1 | 2012 | 581 | 0.080 |
Why?
|
| Breast Neoplasms | 1 | 2016 | 20988 | 0.080 |
Why?
|
| Community Health Centers | 1 | 2012 | 460 | 0.080 |
Why?
|
| Antidepressive Agents, Tricyclic | 1 | 2011 | 432 | 0.080 |
Why?
|
| Canada | 1 | 2014 | 2120 | 0.080 |
Why?
|
| Information Dissemination | 2 | 2014 | 1126 | 0.080 |
Why?
|
| Exercise | 2 | 2016 | 5886 | 0.080 |
Why?
|
| Child | 6 | 2019 | 80089 | 0.080 |
Why?
|
| Inpatients | 2 | 2017 | 2545 | 0.080 |
Why?
|
| Aminophylline | 1 | 2008 | 41 | 0.080 |
Why?
|
| Immunologic Factors | 1 | 2017 | 1589 | 0.080 |
Why?
|
| Proton Pump Inhibitors | 1 | 2013 | 533 | 0.080 |
Why?
|
| Publication Bias | 1 | 2009 | 160 | 0.080 |
Why?
|
| Intracranial Aneurysm | 1 | 2018 | 1285 | 0.080 |
Why?
|
| Multicenter Studies as Topic | 1 | 2013 | 1700 | 0.080 |
Why?
|
| Fluvoxamine | 1 | 2008 | 78 | 0.080 |
Why?
|
| Glucocorticoids | 1 | 2017 | 2160 | 0.080 |
Why?
|
| Antiviral Agents | 1 | 2020 | 3037 | 0.080 |
Why?
|
| Venous Thrombosis | 1 | 2017 | 1303 | 0.080 |
Why?
|
| Theophylline | 1 | 2008 | 131 | 0.070 |
Why?
|
| Physicians, Primary Care | 1 | 2014 | 618 | 0.070 |
Why?
|
| Antibiotic Prophylaxis | 1 | 2013 | 637 | 0.070 |
Why?
|
| Barbiturates | 1 | 2008 | 113 | 0.070 |
Why?
|
| Germ-Line Mutation | 1 | 2016 | 1852 | 0.070 |
Why?
|
| Papillomavirus Vaccines | 1 | 2014 | 496 | 0.070 |
Why?
|
| Cross-Sectional Studies | 8 | 2020 | 26065 | 0.070 |
Why?
|
| Fluorobenzenes | 1 | 2009 | 179 | 0.070 |
Why?
|
| Benzimidazoles | 1 | 2012 | 858 | 0.070 |
Why?
|
| Risk Adjustment | 1 | 2011 | 600 | 0.070 |
Why?
|
| Memory | 1 | 2016 | 2192 | 0.070 |
Why?
|
| Economic Competition | 2 | 2021 | 219 | 0.070 |
Why?
|
| Software | 2 | 2018 | 4432 | 0.070 |
Why?
|
| Postpartum Period | 1 | 2013 | 1178 | 0.070 |
Why?
|
| Self Report | 2 | 2020 | 3727 | 0.070 |
Why?
|
| Pain | 2 | 2022 | 5062 | 0.070 |
Why?
|
| Drug Design | 1 | 2011 | 1045 | 0.070 |
Why?
|
| Stents | 1 | 2018 | 3177 | 0.070 |
Why?
|
| Intention to Treat Analysis | 2 | 2018 | 413 | 0.070 |
Why?
|
| Acute Disease | 2 | 2014 | 7236 | 0.070 |
Why?
|
| Tumor Necrosis Factor-alpha | 1 | 2017 | 4340 | 0.070 |
Why?
|
| Weight Loss | 1 | 2018 | 2682 | 0.070 |
Why?
|
| Qualitative Research | 4 | 2018 | 3017 | 0.070 |
Why?
|
| Smoking Cessation | 2 | 2015 | 2056 | 0.070 |
Why?
|
| Longitudinal Studies | 3 | 2021 | 14599 | 0.070 |
Why?
|
| Pilot Projects | 5 | 2018 | 8619 | 0.070 |
Why?
|
| Informed Consent | 1 | 2012 | 1007 | 0.070 |
Why?
|
| Attitude to Health | 1 | 2015 | 2025 | 0.070 |
Why?
|
| Occupational Diseases | 1 | 2014 | 1490 | 0.060 |
Why?
|
| Antineoplastic Agents | 3 | 2018 | 13635 | 0.060 |
Why?
|
| Health Benefit Plans, Employee | 1 | 2008 | 332 | 0.060 |
Why?
|
| Polysaccharides | 1 | 2012 | 1013 | 0.060 |
Why?
|
| Abnormalities, Drug-Induced | 1 | 2008 | 339 | 0.060 |
Why?
|
| Absenteeism | 1 | 2007 | 247 | 0.060 |
Why?
|
| Carcinoma, Renal Cell | 1 | 2020 | 3164 | 0.060 |
Why?
|
| Quinolines | 1 | 2011 | 764 | 0.060 |
Why?
|
| Thyroid Neoplasms | 1 | 2018 | 2332 | 0.060 |
Why?
|
| Child, Preschool | 4 | 2019 | 42193 | 0.060 |
Why?
|
| Ischemia | 1 | 2014 | 1885 | 0.060 |
Why?
|
| Survival Rate | 3 | 2018 | 12719 | 0.060 |
Why?
|
| Medical Oncology | 1 | 2017 | 2317 | 0.060 |
Why?
|
| Fructose | 1 | 2007 | 288 | 0.060 |
Why?
|
| Predictive Value of Tests | 2 | 2012 | 15250 | 0.060 |
Why?
|
| Anticholesteremic Agents | 1 | 2012 | 967 | 0.060 |
Why?
|
| Medicare Part C | 2 | 2021 | 330 | 0.060 |
Why?
|
| Stroke Volume | 1 | 2018 | 5486 | 0.060 |
Why?
|
| Patient-Centered Care | 1 | 2014 | 1419 | 0.060 |
Why?
|
| Education, Medical, Graduate | 1 | 2016 | 2373 | 0.060 |
Why?
|
| Life Style | 1 | 2016 | 3907 | 0.060 |
Why?
|
| Pulmonary Embolism | 1 | 2017 | 2568 | 0.060 |
Why?
|
| Evidence-Based Practice | 2 | 2018 | 494 | 0.060 |
Why?
|
| Erythrocyte Transfusion | 1 | 2009 | 568 | 0.060 |
Why?
|
| Parents | 1 | 2018 | 3563 | 0.060 |
Why?
|
| Kidney Neoplasms | 1 | 2020 | 4252 | 0.060 |
Why?
|
| Cross Infection | 1 | 2013 | 1422 | 0.060 |
Why?
|
| Efficiency | 1 | 2007 | 476 | 0.060 |
Why?
|
| Multiple Sclerosis | 1 | 2019 | 3222 | 0.060 |
Why?
|
| Surgical Wound Infection | 1 | 2013 | 1529 | 0.060 |
Why?
|
| Communication | 1 | 2018 | 3851 | 0.060 |
Why?
|
| High-Throughput Nucleotide Sequencing | 1 | 2016 | 3634 | 0.050 |
Why?
|
| Prevalence | 2 | 2018 | 15702 | 0.050 |
Why?
|
| Norfloxacin | 1 | 2022 | 24 | 0.050 |
Why?
|
| Inflammatory Bowel Diseases | 1 | 2017 | 2423 | 0.050 |
Why?
|
| Body Mass Index | 1 | 2020 | 12942 | 0.050 |
Why?
|
| Publishing | 1 | 2010 | 832 | 0.050 |
Why?
|
| Pediatrics | 1 | 2016 | 3589 | 0.050 |
Why?
|
| Fetus | 1 | 2008 | 1862 | 0.050 |
Why?
|
| Pancreatic Neoplasms | 1 | 2018 | 5369 | 0.050 |
Why?
|
| Headache | 1 | 2009 | 1255 | 0.050 |
Why?
|
| Epoetin Alfa | 1 | 2020 | 78 | 0.050 |
Why?
|
| Quality Indicators, Health Care | 2 | 2008 | 1790 | 0.040 |
Why?
|
| Pandemics | 1 | 2020 | 8652 | 0.040 |
Why?
|
| Naltrexone | 1 | 2003 | 317 | 0.040 |
Why?
|
| Postoperative Complications | 2 | 2013 | 15609 | 0.040 |
Why?
|
| Neuroprotective Agents | 1 | 2007 | 957 | 0.040 |
Why?
|
| Osteoporosis | 1 | 2010 | 1604 | 0.040 |
Why?
|
| Massachusetts | 3 | 2021 | 8835 | 0.040 |
Why?
|
| Health Education | 1 | 2006 | 1049 | 0.040 |
Why?
|
| Infant | 2 | 2019 | 36157 | 0.040 |
Why?
|
| Insurance Carriers | 1 | 2021 | 155 | 0.040 |
Why?
|
| Renal Dialysis | 1 | 2009 | 1795 | 0.040 |
Why?
|
| Cognition Disorders | 1 | 2013 | 3979 | 0.040 |
Why?
|
| Toluidines | 1 | 2019 | 21 | 0.040 |
Why?
|
| Crotonates | 1 | 2019 | 21 | 0.040 |
Why?
|
| Complementary Therapies | 1 | 2003 | 486 | 0.040 |
Why?
|
| Telemedicine | 1 | 2016 | 3051 | 0.040 |
Why?
|
| Hydroxybutyrates | 1 | 2019 | 76 | 0.040 |
Why?
|
| Coronary Artery Disease | 1 | 2018 | 6403 | 0.040 |
Why?
|
| Multiple Myeloma | 1 | 2016 | 5144 | 0.040 |
Why?
|
| Glucagon-Like Peptides | 1 | 2020 | 153 | 0.040 |
Why?
|
| Infant, Newborn | 1 | 2019 | 26183 | 0.040 |
Why?
|
| Terminology as Topic | 2 | 2017 | 1528 | 0.040 |
Why?
|
| Quality Assurance, Health Care | 1 | 2008 | 2164 | 0.040 |
Why?
|
| Immunoglobulin Fc Fragments | 1 | 2020 | 280 | 0.040 |
Why?
|
| Fluoxetine | 1 | 2022 | 733 | 0.040 |
Why?
|
| Remote Consultation | 1 | 2020 | 237 | 0.040 |
Why?
|
| Cost Sharing | 1 | 2021 | 409 | 0.040 |
Why?
|
| Aging | 1 | 2016 | 8700 | 0.040 |
Why?
|
| Sample Size | 1 | 2021 | 838 | 0.040 |
Why?
|
| Isotretinoin | 1 | 2019 | 134 | 0.040 |
Why?
|
| Validation Studies as Topic | 1 | 2017 | 162 | 0.040 |
Why?
|
| California | 1 | 2021 | 1431 | 0.030 |
Why?
|
| C-Reactive Protein | 1 | 2009 | 3820 | 0.030 |
Why?
|
| Depressive Disorder | 1 | 2009 | 3735 | 0.030 |
Why?
|
| Pyrimidines | 1 | 2009 | 3027 | 0.030 |
Why?
|
| Internship and Residency | 1 | 2016 | 5878 | 0.030 |
Why?
|
| Area Under Curve | 1 | 2020 | 1635 | 0.030 |
Why?
|
| Community Health Planning | 1 | 2016 | 164 | 0.030 |
Why?
|
| Brain Infarction | 1 | 2018 | 289 | 0.030 |
Why?
|
| Budgets | 1 | 2017 | 230 | 0.030 |
Why?
|
| Coronary Disease | 1 | 2010 | 5911 | 0.030 |
Why?
|
| Phenprocoumon | 1 | 2014 | 19 | 0.030 |
Why?
|
| Insurance Benefits | 1 | 2016 | 187 | 0.030 |
Why?
|
| Patient Simulation | 1 | 2017 | 298 | 0.030 |
Why?
|
| Poisson Distribution | 1 | 2016 | 504 | 0.030 |
Why?
|
| Health Care Rationing | 1 | 2018 | 436 | 0.030 |
Why?
|
| Dermatologic Agents | 1 | 2019 | 313 | 0.030 |
Why?
|
| United States Dept. of Health and Human Services | 1 | 2014 | 88 | 0.030 |
Why?
|
| Interviews as Topic | 3 | 2008 | 2697 | 0.030 |
Why?
|
| Health Promotion | 1 | 2006 | 2206 | 0.030 |
Why?
|
| Continuity of Patient Care | 1 | 2021 | 1067 | 0.030 |
Why?
|
| Computer Communication Networks | 1 | 2016 | 293 | 0.030 |
Why?
|
| Probability | 1 | 2019 | 2475 | 0.030 |
Why?
|
| Health Insurance Portability and Accountability Act | 1 | 2014 | 105 | 0.030 |
Why?
|
| Tramadol | 1 | 2014 | 60 | 0.030 |
Why?
|
| Opioid-Related Disorders | 2 | 2020 | 2164 | 0.030 |
Why?
|
| Professional Role | 1 | 2017 | 313 | 0.030 |
Why?
|
| Physician-Patient Relations | 2 | 2018 | 3239 | 0.030 |
Why?
|
| Nausea | 1 | 2017 | 679 | 0.030 |
Why?
|
| Professional-Family Relations | 1 | 2018 | 495 | 0.030 |
Why?
|
| Policy | 1 | 2017 | 506 | 0.030 |
Why?
|
| Nitriles | 1 | 2019 | 971 | 0.030 |
Why?
|
| Standard of Care | 1 | 2017 | 551 | 0.030 |
Why?
|
| Colorectal Neoplasms | 1 | 2013 | 6927 | 0.030 |
Why?
|
| Pathology, Molecular | 1 | 2016 | 329 | 0.030 |
Why?
|
| Diabetic Angiopathies | 1 | 2018 | 803 | 0.030 |
Why?
|
| Suicidal Ideation | 1 | 2022 | 1447 | 0.030 |
Why?
|
| Peptic Ulcer | 1 | 2013 | 217 | 0.020 |
Why?
|
| Community-Based Participatory Research | 1 | 2014 | 221 | 0.020 |
Why?
|
| ROC Curve | 1 | 2019 | 3575 | 0.020 |
Why?
|
| Nurse Practitioners | 1 | 2014 | 269 | 0.020 |
Why?
|
| Drug Carriers | 1 | 2016 | 706 | 0.020 |
Why?
|
| Recombinant Fusion Proteins | 1 | 2020 | 3730 | 0.020 |
Why?
|
| Computer Security | 1 | 2013 | 260 | 0.020 |
Why?
|
| Recombinant Proteins | 1 | 2020 | 6520 | 0.020 |
Why?
|
| Incidental Findings | 1 | 2016 | 697 | 0.020 |
Why?
|
| Causality | 1 | 2017 | 1241 | 0.020 |
Why?
|
| Chemoprevention | 1 | 2013 | 325 | 0.020 |
Why?
|
| Age Distribution | 1 | 2016 | 2872 | 0.020 |
Why?
|
| Rupture | 1 | 2012 | 443 | 0.020 |
Why?
|
| Creatinine | 1 | 2016 | 1895 | 0.020 |
Why?
|
| Lung Neoplasms | 1 | 2015 | 13383 | 0.020 |
Why?
|
| Emergency Medical Services | 1 | 2022 | 1921 | 0.020 |
Why?
|
| Government Regulation | 1 | 2014 | 524 | 0.020 |
Why?
|
| Analgesics | 1 | 2017 | 1067 | 0.020 |
Why?
|
| Europe | 1 | 2017 | 3415 | 0.020 |
Why?
|
| Alzheimer Disease | 1 | 2011 | 8603 | 0.020 |
Why?
|
| Achilles Tendon | 1 | 2012 | 180 | 0.020 |
Why?
|
| Hospitals | 1 | 2022 | 3879 | 0.020 |
Why?
|
| Income | 1 | 2017 | 1870 | 0.020 |
Why?
|
| Clinical Trials, Phase III as Topic | 1 | 2012 | 857 | 0.020 |
Why?
|
| Multivariate Analysis | 2 | 2013 | 12043 | 0.020 |
Why?
|
| Motivation | 1 | 2018 | 2003 | 0.020 |
Why?
|
| Patient Participation | 1 | 2017 | 1443 | 0.020 |
Why?
|
| Acute Kidney Injury | 1 | 2020 | 1923 | 0.020 |
Why?
|
| Dyslipidemias | 1 | 2015 | 868 | 0.020 |
Why?
|
| Immunotherapy | 1 | 2003 | 4642 | 0.020 |
Why?
|
| Cause of Death | 1 | 2018 | 3683 | 0.020 |
Why?
|
| Adaptation, Psychological | 1 | 2018 | 2632 | 0.020 |
Why?
|
| Patient Selection | 1 | 2018 | 4237 | 0.020 |
Why?
|
| Boston | 1 | 2019 | 9313 | 0.020 |
Why?
|
| Stress, Physiological | 1 | 2013 | 1403 | 0.020 |
Why?
|
| Patient Discharge | 1 | 2018 | 3442 | 0.020 |
Why?
|
| Liver | 1 | 2020 | 7512 | 0.020 |
Why?
|
| Anti-Infective Agents | 1 | 2012 | 983 | 0.010 |
Why?
|
| Societies, Medical | 1 | 2017 | 3901 | 0.010 |
Why?
|
| Guideline Adherence | 1 | 2014 | 2218 | 0.010 |
Why?
|
| Glucose | 1 | 2016 | 4345 | 0.010 |
Why?
|
| Health Surveys | 1 | 2014 | 4036 | 0.010 |
Why?
|
| Psychometrics | 1 | 2013 | 3062 | 0.010 |
Why?
|
| Curriculum | 1 | 2016 | 3739 | 0.010 |
Why?
|
| Genome, Human | 1 | 2016 | 4421 | 0.010 |
Why?
|
| Papillomavirus Infections | 1 | 2014 | 1612 | 0.010 |
Why?
|
| Linear Models | 1 | 2011 | 5866 | 0.010 |
Why?
|
| Statistics, Nonparametric | 1 | 2007 | 2851 | 0.010 |
Why?
|
| Clinical Competence | 1 | 2016 | 4790 | 0.010 |
Why?
|
| Animals | 2 | 2012 | 168202 | 0.010 |
Why?
|
| Healthcare Disparities | 1 | 2015 | 3351 | 0.010 |
Why?
|
| Residence Characteristics | 1 | 2006 | 2092 | 0.010 |
Why?
|
| Blood Pressure | 1 | 2011 | 8473 | 0.010 |
Why?
|
| Health Behavior | 1 | 2006 | 2643 | 0.010 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2016 | 17878 | 0.010 |
Why?
|
| Double-Blind Method | 1 | 2007 | 12333 | 0.010 |
Why?
|